Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
47°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Paxmedica Inc
(NQ:
PXMD
)
0.6883
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Paxmedica Inc
< Previous
1
2
3
4
Next >
Chinese Researchers Notch Major Milestone in Developing Gene Editing System Against Autism
December 13, 2023
Via
Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) CEO Featured in Just-Released Fireside Chat Video
December 06, 2023
Via
Investor Brand Network
Exposures
Product Safety
PaxMedica Inc. (NASDAQ: PXMD) Completes Key Type-B FDA Meeting, Discussing Positive Results from PAX-HAT-301 Study
December 06, 2023
Via
Investor Brand Network
Exposures
Product Safety
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman
December 06, 2023
Via
ACCESSWIRE
PaxMedica Inc. (NASDAQ: PXMD) Closes Public Offering of Approximately $7 Million and Continues Pursuing ASD Pipeline
December 05, 2023
Via
Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Featured in Recent H.C. Wainwright & Co. Research Report with ‘Buy’ Rating, $3 PT
December 04, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Study Shows Autistic People Have Lower Life Expectancy Than General Population
December 01, 2023
Via
Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Closes on Public Offering Reaching Estimated $7M
November 27, 2023
Via
Investor Brand Network
PaxMedica Announces Closing of $7.0 Million Public Offering
November 22, 2023
Via
ACCESSWIRE
BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Announces Pricing of $7M Public Offering
November 20, 2023
Via
Investor Brand Network
PaxMedica Announces Pricing of $7.0 Million Public Offering
November 20, 2023
Via
ACCESSWIRE
Study Examines Role of African Sleeping Sickness in Body Wasting
November 17, 2023
Via
Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) News of FDA Type-B Meeting Shared in Syndicated Audio Broadcast
November 17, 2023
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Releases Q3 2023 Financial Report, Corporate Update
November 16, 2023
Via
Investor Brand Network
Exposures
Product Safety
PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update
November 15, 2023
Via
ACCESSWIRE
PaxMedica Inc. (NASDAQ: PXMD) Is Hoping to Boost Patient Independence with Potential ASD Treatment Amid Growing Prevalence Rates
November 14, 2023
Via
Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) CMO Featured in Latest Bell2Bell Podcast Release
November 09, 2023
Via
Investor Brand Network
Exposures
Product Safety
Study Finds Autism Compromises Sleep Quality, Physical Activity in Kids
November 07, 2023
Via
Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Phase 2 Study Results Published in Peer-Reviewed Journal
November 07, 2023
Via
Investor Brand Network
PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal
November 07, 2023
Via
ACCESSWIRE
PaxMedica Inc. (NASDAQ: PXMD) PRV Sale Prospects Strengthened by Recent Industry Developments
November 03, 2023
Via
Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD), Bourne Partners to Collaborate in Evaluating Future Monetization of Potential PRV
November 02, 2023
Via
Investor Brand Network
Exposures
Product Safety
PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)
November 02, 2023
From
PaxMedica, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Acquires Research Assets to Accelerate PAX-101 NDA Submission
October 31, 2023
Via
Investor Brand Network
PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101
October 31, 2023
From
PaxMedica, Inc.
Via
GlobeNewswire
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Reports on 1-for-17 Reverse Stock Split
October 30, 2023
Via
Investor Brand Network
PaxMedica Announces 1-for-17 Reverse Stock Split
October 30, 2023
From
PaxMedica, Inc.
Via
GlobeNewswire
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Reports on Publication of Low-Dose Suramin for ASD Research
October 27, 2023
Via
Investor Brand Network
PaxMedica Inc.’s (NASDAQ: PXMD) CEO and Corporate Communications Chief Discuss Regulatory Strategy for Lead Drug Candidate and Future Plans in Recent Bell2Bell Podcast Interview
October 27, 2023
Via
Investor Brand Network
BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Clearing Path to Submit NDA for PAX-101
October 26, 2023
Via
Investor Brand Network
Exposures
Product Safety
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.